^
7ms
Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 (clinicaltrials.gov)
P1, N=37, Recruiting, AvenCell Europe GmbH | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Dec 2025
Trial completion date • Trial primary completion date • Combination therapy
|
IL3RA (Interleukin 3 Receptor Subunit Alpha)
|
CD123 expression
|
cyclophosphamide • fludarabine IV • AVC-201
9ms
Enrollment open
|
IL3RA (Interleukin 3 Receptor Subunit Alpha)
|
CD123 expression
|
cyclophosphamide • fludarabine IV • AVC-201
1year
Functional Characterization and Optimization of Switchable Allogeneic Chimeric Antigen Receptor T Cells for Targeting CD19 and CD20 in B Cell Malignancies (ASH 2023)
A summary of functional characterization data will be presented at the meeting with a focus on the lack of predictability of certain in vitro models and underlying hypotheses. Insights from these studies are now flowing into preclinical development of a novel switchable allogeneic CAR-T cell product candidate targeting CD19 and CD20 in B cell malignancies engineered to fully overcome graft-versus-host disease as well as graft rejection by host T and NK cells.
CAR T-Cell Therapy
|
CD123 (Interleukin 3 Receptor Subunit Alpha) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
|
CD123 positive • IL3RA positive
|
AVC-201
over1year
New P1 trial • Combination therapy
|
IL3RA (Interleukin 3 Receptor Subunit Alpha)
|
CD123 expression
|
cyclophosphamide • fludarabine IV • AVC-201